212 related articles for article (PubMed ID: 34417327)
1. Tuberous Sclerosis Complex (TSC) Inactivation Increases Neuronal Network Activity by Enhancing Ca
Hisatsune C; Shimada T; Miyamoto A; Lee A; Yamagata K
J Neurosci; 2021 Sep; 41(39):8134-8149. PubMed ID: 34417327
[TBL] [Abstract][Full Text] [Related]
2. Tuberous sclerosis: a review of the past, present, and future.
Uysal SP; Şahin M
Turk J Med Sci; 2020 Nov; 50(SI-2):1665-1676. PubMed ID: 32222129
[TBL] [Abstract][Full Text] [Related]
3. High glucose concentrations mask cellular phenotypes in a stem cell model of tuberous sclerosis complex.
Rocktäschel P; Sen A; Cader MZ
Epilepsy Behav; 2019 Dec; 101(Pt B):106581. PubMed ID: 31761686
[TBL] [Abstract][Full Text] [Related]
4. A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway.
Fu J; Liang P; Zheng Y; Xu C; Xiong F; Yang F
Gene; 2024 May; 909():148312. PubMed ID: 38412945
[TBL] [Abstract][Full Text] [Related]
5. The non-essential TSC complex component TBC1D7 restricts tissue mTORC1 signaling and brain and neuron growth.
Schrötter S; Yuskaitis CJ; MacArthur MR; Mitchell SJ; Hosios AM; Osipovich M; Torrence ME; Mitchell JR; Hoxhaj G; Sahin M; Manning BD
Cell Rep; 2022 May; 39(7):110824. PubMed ID: 35584673
[TBL] [Abstract][Full Text] [Related]
6. Revisiting Brain Tuberous Sclerosis Complex in Rat and Human: Shared Molecular and Cellular Pathology Leads to Distinct Neurophysiological and Behavioral Phenotypes.
Kútna V; O'Leary VB; Newman E; Hoschl C; Ovsepian SV
Neurotherapeutics; 2021 Apr; 18(2):845-858. PubMed ID: 33398801
[TBL] [Abstract][Full Text] [Related]
7. Ornithine decarboxylase, the rate-limiting enzyme of polyamine synthesis, modifies brain pathology in a mouse model of tuberous sclerosis complex.
Kapfhamer D; McKenna J; Yoon CJ; Murray-Stewart T; Casero RA; Gambello MJ
Hum Mol Genet; 2020 Aug; 29(14):2395-2407. PubMed ID: 32588887
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Novel TSC2 c.170G>A Missense Variant: A Case Report and Elaboration on the Yield of Targeted Options against Tuberous Sclerosis Complex Manifestations.
Papageorgiou G; Skouteris N; Valavanis C; Stanc GM; Souka E; Charalampakis N
Rev Recent Clin Trials; 2023; 18(4):304-312. PubMed ID: 37877150
[TBL] [Abstract][Full Text] [Related]
9. Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways-Case Report and Literature Review.
Jurca CM; Kozma K; Petchesi CD; Zaha DC; Magyar I; Munteanu M; Faur L; Jurca A; Bembea D; Severin E; Jurca AD
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833359
[TBL] [Abstract][Full Text] [Related]
10. Modeling tuberous sclerosis complex with human induced pluripotent stem cells.
Niu W; Siciliano B; Wen Z
World J Pediatr; 2024 Mar; 20(3):208-218. PubMed ID: 35759110
[TBL] [Abstract][Full Text] [Related]
11. Two different genetic etiologies for tuberous sclerosis complex (TSC) in a single family.
Mowrey K; Koenig MK; Szabo CA; Samuels J; Mulligan S; Pearson DA; Northrup H
Mol Genet Genomic Med; 2020 Jul; 8(7):e1296. PubMed ID: 32383331
[TBL] [Abstract][Full Text] [Related]
12. Tuberous Sclerosis Complex Genotypes and Developmental Phenotype.
Farach LS; Pearson DA; Woodhouse JP; Schraw JM; Sahin M; Krueger DA; Wu JY; Bebin EM; Lupo PJ; Au KS; Northrup H;
Pediatr Neurol; 2019 Jul; 96():58-63. PubMed ID: 31005478
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into TSC complex assembly and GAP activity on Rheb.
Yang H; Yu Z; Chen X; Li J; Li N; Cheng J; Gao N; Yuan HX; Ye D; Guan KL; Xu Y
Nat Commun; 2021 Jan; 12(1):339. PubMed ID: 33436626
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic studies identify changes in transmethylation and polyamine metabolism in a brain-specific mouse model of tuberous sclerosis complex.
McKenna J; Kapfhamer D; Kinchen JM; Wasek B; Dunworth M; Murray-Stewart T; Bottiglieri T; Casero RA; Gambello MJ
Hum Mol Genet; 2018 Jun; 27(12):2113-2124. PubMed ID: 29635516
[TBL] [Abstract][Full Text] [Related]
15. Rescue of impaired blood-brain barrier in tuberous sclerosis complex patient derived neurovascular unit.
Brown JA; Faley SL; Judge M; Ward P; Ihrie RA; Carson R; Armstrong L; Sahin M; Wikswo JP; Ess KC; Neely MD
J Neurodev Disord; 2024 May; 16(1):27. PubMed ID: 38783199
[TBL] [Abstract][Full Text] [Related]
16. The role of TSC1 and TSC2 proteins in neuronal axons.
Karalis V; Wood D; Teaney NA; Sahin M
Mol Psychiatry; 2024 Jan; ():. PubMed ID: 38212374
[TBL] [Abstract][Full Text] [Related]
17. Heterozygous loss of TSC2 alters p53 signaling and human stem cell reprogramming.
Armstrong LC; Westlake G; Snow JP; Cawthon B; Armour E; Bowman AB; Ess KC
Hum Mol Genet; 2017 Dec; 26(23):4629-4641. PubMed ID: 28973543
[TBL] [Abstract][Full Text] [Related]
18. Tsc1-mTORC1 signaling controls striatal dopamine release and cognitive flexibility.
Kosillo P; Doig NM; Ahmed KM; Agopyan-Miu AHCW; Wong CD; Conyers L; Threlfell S; Magill PJ; Bateup HS
Nat Commun; 2019 Nov; 10(1):5426. PubMed ID: 31780742
[TBL] [Abstract][Full Text] [Related]
19. mTOR Inhibitors in Tuberous Sclerosis Complex.
Curatolo P; Moavero R
Curr Neuropharmacol; 2012 Dec; 10(4):404-15. PubMed ID: 23730262
[TBL] [Abstract][Full Text] [Related]
20. Is tuberous sclerosis complex-associated autism a preventable and treatable disorder?
Curatolo P; Scheper M; Emberti Gialloreti L; Specchio N; Aronica E
World J Pediatr; 2024 Jan; 20(1):40-53. PubMed ID: 37878130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
